TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02850185

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oxyhydrogen
Description: Hydrogen/oxygen mixed gas inhaled(proportion 2:1),3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: oxygen inhaled,3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Bronchodilator (LABA,LAMA) with or without ICS.Conventional treatment is invariable with which was given to COPD patients in 3 months before the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Bronchodilator (LABA,LAMA) with or without ICS.Conventional treatment is invariable with which was given to COPD patients in 3 months before the study.
Study: NCT03360955

Intervention type: PROCEDURE
Intervention: Anesthesia
Description: Different anesthesia technique will be compared to find out which one offers better outcome to perform ultrafast track extubation

Intervention type: PROCEDURE
Intervention: Anesthesia
Description: Different anesthesia technique will be compared to find out which one offers better outcome to perform ultrafast track extubation
Study: NCT04222855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: Puerperal patients was administered (60 mg) orally every 8 hours with diltiazem (tables).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diltiazem
Description: Puerperal patients was administered (60 mg) orally every 8 hours with diltiazem (tables).
Study: NCT04334564

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo biloba capsule
Description: Ginkgo biloba capsule may improve visual function of primary open-angle glaucoma by repairing of the optic nerve.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebos were controls.
Study: NCT02678884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18-F FDG
Description: All patients enrolled in this study will receive 2 PET Scans: One prior to Radiation, and one during Radiation.
Study: NCT02049138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet taken orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent conjugate vaccine (PCV-13)
Description: Administered by intramuscular injection
Study: NCT04419480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioMEMS implantation with routine ambulatory pulmonary artery pressure monitoring and medication optimization
Description: Implantation of CardioMEMS Device in patients following admission for Cardiogenic shock, with regular ambulatory pulmonary artery pressure monitoring and medication optimization for the treatment of heart failure.
Study: NCT00552760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: one 8 mg tablet at bedtime for up to 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet at bedtime for up to 6 months
Study: NCT00951756

Intervention type: OTHER
Group type: OTHER
Intervention: High fat diet
Description: High fat diet and low fat diet are composed of the same food, but the portion sizes are varied.

Intervention type: OTHER
Group type: OTHER
Intervention: High fat diet
Description: High fat diet and low fat diet are composed of the same food, but the portion sizes are varied.
Study: NCT06505538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NL-Mapp
Description: Mobile applicaiton
Study: NCT01119677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avonex
Description: Group 1 subjects will receive weekly Avonex 30 mcg (full dose) IM injections from Week 1 to Week 8. Group 2 subjects will titrate in quarter dose increments every week up to a full dose of Avonex over a 3 week period from Week 1 to Week 3 and then continue on full dose from Week 4 to Week 8. Group 3 subjects will titrate in quarter dose increments every 2 weeks up to a full dose of Avonex over a 6 week period from Week 1 to Week 6 and continue on full dose from Week 7 to Week 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avonex
Description: Group 1 subjects will receive weekly Avonex 30 mcg (full dose) IM injections from Week 1 to Week 8. Group 2 subjects will titrate in quarter dose increments every week up to a full dose of Avonex over a 3 week period from Week 1 to Week 3 and then continue on full dose from Week 4 to Week 8. Group 3 subjects will titrate in quarter dose increments every 2 weeks up to a full dose of Avonex over a 6 week period from Week 1 to Week 6 and continue on full dose from Week 7 to Week 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avonex
Description: Group 1 subjects will receive weekly Avonex 30 mcg (full dose) IM injections from Week 1 to Week 8. Group 2 subjects will titrate in quarter dose increments every week up to a full dose of Avonex over a 3 week period from Week 1 to Week 3 and then continue on full dose from Week 4 to Week 8. Group 3 subjects will titrate in quarter dose increments every 2 weeks up to a full dose of Avonex over a 6 week period from Week 1 to Week 6 and continue on full dose from Week 7 to Week 8
Study: NCT02498457

Intervention type: OTHER
Group type: OTHER
Intervention: low calcium dialysis
Description: patients in this group will receive low calcium dialysis for 1 year.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low calcium dialysis
Description: patients in this group will receive low calcium dialysis for 1 year.
Study: NCT02610244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Cogmed Training
Description: Comparison of outcome measures between treatment-as-usual group and Modified Cogmed Training group after 10 weeks and 3 months follow up.
Study: NCT02570880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glycemic index (glucose-solution, bread samples)
Description: All participants will test 2 breads, prepared with different fermentation times of dough, both breads will be tested in duplicate. Methode: International Organization for Standardization / Final Draft International Standard 26642, Food products - Determination of the glycaemic index (GI) and recommendation for food classification
Study: NCT00369694

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: 2 mg Terlipressin stat, then 1 mg q6h for total of 72 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Terlipressin & then Dummy
Description: 2 mg Terlipressin stat then 1 mg q6 hours for 24 hours, then a Dummy of Terlipressin q6 hours for the next 48 hours.
Study: NCT00801047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine epidural
Description: Bupivacaine 0.1%, fentanyl 1 mic/kg
Study: NCT03459742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamification strategy
Description: The intervention is a gamification strategy, including game elements such as points, levels and rewards. Points are scored by completion of healthy challenges, i.e. a healthy snacks challenge, a steps challenge and activity challenge. Intervention takes place for 8 months from Mar to Nov. There will be three levels. Level 1 at baseline, level 2 expected at month 4 by 100% of participants and level 3 expected in month 8 by 70% of participants. A new cycle will start in 2019.~Rewards include an initial reward (Starting Kit), a structural reward and an activity reward. The Starting Kit is a box with souvenirs, information for students and teachers. A structural reward, at level 2, will be achieved collectively by all participating classes in one school. It consists of school infrastructure improvements to promote a healthy nutrition and PA (eg. climbing wall, shared bicycles, sports equipment). An activity reward (AR), when reaching level 3, consists of a fun and healthy activity.
Study: NCT02063490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence support
Description: One-time preparatory intervention offering adherence prerequisites (knowledge, social support and skills)~+ One-year monthly individualised counselling sessions with a standardised intervention sheet listing the most prevalent problems with possible solutions
Study: NCT00149487

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tailored Problem Solving Intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Problem Solving Intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Education Intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Education Intervention
Study: NCT00712829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 123-I-MIP-1072
Description: 10 mCi intravenous injection given one time during the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 123-I-MIP-1072
Description: 10 mCi intravenous injection given one time during the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 123-I-MIP-1095
Description: 10 mCi intravenous injection given one time during the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 123-I-MIP-1095
Description: 10 mCi intravenous injection given one time during the study
Study: NCT01264146

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HBOT
Description: Open reduction and internal fixation of calcaneal fracture + hyperbaric oxygen therapy 20 postoperative days (one time, 90 minutes a day)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Sham)
Description: open reduction and internal fixation of calcaneal fracture + Placebo (Sham)
Study: NCT03674242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eryaspase (L-asparaginase encapsulated in red blood cells)
Description: IV infusion 100 U/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: IV infusion 1000 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion 1000 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion AUC2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion AUC2
Study: NCT03619187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Ivabradine will be provided in bottles (60 tablets per bottle) labeled ivabradine 5 mg and ivabradine 7.5 mg. The 2.5 mg dose of ivabradine will be achieved by subjects splitting the 5 mg tablets into equal halves.
Study: NCT03191760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Participants will be asked to attend 6 in-person or phone-mediated therapy sessions lasting approximately 45 minutes per session, to be held in Primary Care settings. Content of therapy sessions includes education about PTSD symptoms, discussion of the role of avoidance in maintaining PTSD symptoms, self-monitoring homework to identify links between activity level and emotions, and homework designed to increase engagement in valued activities, with a focus on increasing social contact and support. If relevant, participants will be instructed in basic communication skills, social skills, and relaxation skills.
Study: NCT02537054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Intravitreal injection
Study: NCT03164343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education for children
Description: Children and their parent will receive a +/- 1h one-on-one educational session about the neurophysiology of pain, adjusted to the child's comprehension status. Parents will be present in the PNE session too. The PNE program for children contains two sections: (1) The healthy pain system and its function, divided in subsections each consisting of a specific neurophysiological pain concept (i.e. central nervous system anatomy, nociception and nociceptive pathways, up- and down-regulation of the nervous system) and (2) adaptations of the pain system following persistent pain. To ensure interaction between therapist and child, an interactive board game was developed and used throughout the full educational session.
Study: NCT04171687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75mg
Description: Clopidogrel 75 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75mg
Description: Clopidogrel 75 mg tablet
Study: NCT01941576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human brain natriuretic peptide (rhBNP)
Description: Patients are first given a loading dose of recombinant human brain natriuretic peptide (rhBNP) 1.5 mcg/kg, followed by continuous infusion recombinant human brain natriuretic peptide 0.01-0.01mcg/kg/min for 72 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Description: Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a placebo infusion 24 hours after operation.
Study: NCT04171687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75mg
Description: Clopidogrel 75 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan 50 mg
Description: Tegoprazan 50 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAPA113
Description: RAPA113 tablet
Study: NCT06197815

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The assistance type during ERCP
Description: The senior trainer guides the trainees during ERCP procedure outside the operating room using communication equipment and the screen displaying an endoscopic view.
Study: NCT04454112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 24-hour esophageal pH monitoring using an ambulatory system (Ohmega, MMS, Enschede, The Netherlands).
Description: 24-hour esophageal pH monitoring application
Study: NCT06197815

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The assistance type during ERCP
Description: The senior trainer guides the trainees during ERCP procedure outside the operating room using communication equipment and the screen displaying an endoscopic view.
Study: NCT01042236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: Fesoterodine 4 mg and 8 mg and placebo - each dosed for 7 days with 7 day washout between dosing periods
Study: NCT02338960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bremelanotide
Description: A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bremelanotide
Description: A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03721315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The health literacy enhancement will comprise of the following:~* Practical day to day information to help manage the disease~* Benefits of medication and adherence~* Tips to improve managing shortness of breath~* Proper use of inhalers (if applicable)~* Managing daily activities
Study: NCT02859753

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Percutaneous Radiofrequency Ablation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Microwave Ablation
Study: NCT01648114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antenatal Breastfeeding Intervention
Description: The intervention will include a 20 to 30-minute one-to-one educational talk by a lactation expert explaining the facts of breastfeeding and answering participant questions. The educational intervention will focus on: (1) the importance of exclusive breastfeeding, (2) milk supply/demand and feeding on demand, (3) frequency of feedings, feeding cues, how to know an infant is getting enough milk, (4) avoiding artificial nipples until the infant is nursing well, (5) the importance of a good latch, (5) where to seek breastfeeding help and support, and (7) returning to work and continuing breastfeeding
Study: NCT03516877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Stress Resilience Training for Faculty Physicians
Description: Enhanced Stress Resilience Training (ESRT) is derived from Mindfulness-Based Stress Reduction with modifications to language, activities and contextualization to tailor the training to physicians involved in the operating room environment. ESRT consists of 5 weekly 1-hour group classes and 2-4 hour retreat. Classes focus on developing sustained attention and open monitoring in addition to training focused on stress and coping. Increasing duration (3-20 minutes per day) of guided mindfulness exercises are assigned each week. A 2-4 hour intensive retreat occurs at week 4 or 5. The central exercises of the training are the body scan, sitting meditation, qi gong and yoga. The weekly teaching sessions will be offered at various days and times each week in order to accommodate complicated physicians schedules that vary at each site. Participants can attend whichever session is most convenient. Daily practice will occur independently, with the duration reported weekly through text or email.
Study: NCT00923078

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory Cognitive Training
Description: The program entails six computer-based exercises that are designed to be very easy to use and require no computer experience. The exercises are calibrated to individual performance at the onset of training and adapt in difficulty to individual performance, giving constant feedback about progress. Each of the six exercises focuses on a distinct process: (1) auditory processing speed, (2) discriminating sounds, (3) sound precision, (4) sound sequencing, (5) working memory, and (6) narrative memory. Training was administered in a supervised clinical laboratory setting at a frequency of five 60-minute sessions per week over 4 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory Cognitive Training
Description: The program entails six computer-based exercises that are designed to be very easy to use and require no computer experience. The exercises are calibrated to individual performance at the onset of training and adapt in difficulty to individual performance, giving constant feedback about progress. Each of the six exercises focuses on a distinct process: (1) auditory processing speed, (2) discriminating sounds, (3) sound precision, (4) sound sequencing, (5) working memory, and (6) narrative memory. Training was administered in a supervised clinical laboratory setting at a frequency of five 60-minute sessions per week over 4 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Cognitive Training
Description: The program entails five computer-based exercises that are designed to be very easy to use and require no computer experience. The exercises are calibrated to individual performance at the onset of training and, following our laboratory procedures, calibration testing is repeated every 5th session. Exercises adapt in difficulty to individual performance, giving constant feedback about progress. Each of the five exercises focuses on a distinct process: (1) visual precision, (2) visual processing speed, (3) divided attention, (4) visual working memory, and (5) useful field of view. Training was administered in a supervised clinical laboratory setting at a frequency of five 40-minute sessions per week over 4 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Cognitive Training
Description: The program entails five computer-based exercises that are designed to be very easy to use and require no computer experience. The exercises are calibrated to individual performance at the onset of training and, following our laboratory procedures, calibration testing is repeated every 5th session. Exercises adapt in difficulty to individual performance, giving constant feedback about progress. Each of the five exercises focuses on a distinct process: (1) visual precision, (2) visual processing speed, (3) divided attention, (4) visual working memory, and (5) useful field of view. Training was administered in a supervised clinical laboratory setting at a frequency of five 40-minute sessions per week over 4 weeks.
Study: NCT03054506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CSP01
Description: Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carboxymethylcellulose (CMC)
Description: Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.
Study: NCT04326894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg/week oral methotrexate tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 25mg/week oral placebo tablets
Study: NCT04261309

Intervention type: OTHER
Intervention: Usual care
Description: Since this is an observational study there will be no interference with the care given by the primary healthcare providers. However, the usual care provided by these and other healthcare utilization used by the patients during follow-up will be recorded during the follow-ups.
Study: NCT01999335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oprozomib
Description: Extended release (ER) tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oprozomib
Description: Extended release (ER) tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oprozomib
Description: Extended release (ER) tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oprozomib
Description: Extended release (ER) tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oprozomib
Description: Extended release (ER) tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Capsules for oral administration